44.46 USD
▼-0.04-0.09%
盘后 45.00 +1.21%
2026-11-19
市值
$1.75B
市盈率
—
EPS
-4.17
股息率
—
52 周区间
14.72 – 54.78
成交量
433.35K
Beta
—
目标价
75.17
52W 低 14.7252W 高 54.78
价格走势
公司简介
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti‑CD122 antagonist that targets the shared beta subunit of the IL‑15 and IL‑2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2‑modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). Fir...